ReviewFrontiers in immunology2018
Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 69 citations in OpenAlex.
- Autoimmune-associated thrombosis: mechanisms, population burden, and prevention strategies.The Lancet regional health. Europe · 2026Review
- Serum from Patients with Antiphospholipid Syndrome Differentially Affects Venous and Microcirculatory Endothelial Cells.Biology · 2026Article
- Role of monocytes in the pathogenesis of antiphospholipid syndrome and potential therapeutic targets (Review).Molecular medicine reports · 2025Review
- ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry").Rheumatology (Oxford, England) · 2025Article
- Neonatal intracardiac thrombosis secondary to transplacental transfer of maternal antiphospholipid antibodies-a case report and review of the literature.Research and practice in thrombosis and haemostasis · 2025Article
- Extracellular Vesicles Analysis as Possible Signatures of Antiphospholipid Syndrome Clinical Features.International journal of molecular sciences · 2025Article
- A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry.Frontiers in immunology · 2025Article
- Antiphospholipid Antibodies as Key Players in Systemic Lupus Erythematosus: The Relationship with Cytokines and Immune Dysregulation.International journal of molecular sciences · 2024Review
- Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events.Annals of the rheumatic diseases · 2024Article
- [Immunopathogenesis of systemic lupus erythematosus].Zeitschrift fur Rheumatologie · 2024Review
- Article
- Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications.Clinical and experimental immunology · 2023Review
- Lupus anticoagulants as a prospective independent predictor in COVID-19 patients.International journal of laboratory hematology · 2023Article
- A Well-Intentioned Enemy in Autoimmune and Autoinflammatory Diseases: NETosis.Turkish archives of pediatrics · 2023Article
- Antiphospholipid Antibody Syndrome-Associated Increased Surface Expression of VLA4 Integrin on Human Monocytes.Biomedicines · 2022Article
- Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome.International journal of molecular sciences · 2022Article
- Article
- Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review.Journal of clinical medicine · 2022Review
- Pathophysiology of Cardiac Injury in COVID-19 Patients with Acute Ischaemic Stroke: What Do We Know So Far?-A Review of the Current Literature.Life (Basel, Switzerland) · 2022Review
- Evaluation of the Association between Antiphospholipid Antibodies and ICU Admission Outcome in Critically Ill COVID-19 Patients in Iranian Population.International journal of preventive medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary anti-phospholipid syndrome (APS) is characterized by the production of antibodies that bind the phospholipid-binding protein β2 glycoprotein I (β2GPI) or that directly recognize negatively charged membrane phospholipids in a manner that may contribute to arterial or venous thrombosis. Clinically, the binding of antibodies to β2GPI could contribute to pathogenesis by formation of immune complexes or modification of coagulation steps that operate along cell surfaces. However, additional events are likely to play a role in pathogenesis, including platelet and endothelial cell activation. Recent studies focus on neutrophil release of chromatin in the form of neutrophil extracellular traps as an important disease contributor. Jointly, the participation of both the innate and adaptive arms of the immune system in aspects of the APS make the complete understanding of crucial steps in pathogenesis extremely difficult. Only coordinated and comprehensive analyses, carried out in different clinical and research settings, are likely to advance the understanding of this complex disease condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.